A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer

• Main Authors: R. Portner, A. Bajaj, T. Elumalai, R. Huddart, V. Murthy, H. Nightingale, K. Patel, P. Sargos, Y. Song, P. Hoskin, A. Choudhury
• Format: Article
• Language: English
• Published: Elsevier 2021-11-01
• Series: Clinical and Translational Radiation Oncology
• Subjects: Associated-muscle-invasive bladder cancer; Bladder preservation; Radiotherapy; Radiosensitisation; Adaptive radiotherapy
• Online Access: http://www.sciencedirect.com/science/article/pii/S2405630821000720

Bladder preservation with trimodality treatment (TMT) is an alternative strategy to radical cystectomy (RC) for the management of localised muscle invasive bladder cancer (MIBC). TMT comprises of transurethral resection of the bladder tumour (TURBT) followed by radiotherapy with concurrent radiosensitisation. TMT studies have shown neo-adjuvant chemotherapy with cisplatin-based regimens is often given to further improve survival outcomes. A hypofractionated radiotherapy regimen is preferable due to its non-inferiority in local control and late toxicities. Radiosensitisation can comprise concurrent chemotherapy (with gemcitabine, cisplatin or combination fluorouracil and mitomycin), CON (carbogen and nicotinomide) or hyperthermic treatment.Radiotherapy techniques are continuously improving and becoming more personalised. As the bladder is a mobile structure subject to volumetric changes from filling, an adaptive approach can optimise bladder coverage and reduce dose to normal tissue. Adaptive radiotherapy (ART) is an evolving field that aims to overcome this. Improved knowledge of tumour biology and advances in imaging techniques aims to further optimise and personalise treatment.